Improving Survival In Oncogene Driven Lung Cancer

Artificial intelligence (AI) is transforming medicine. Lung Cancer healthcare professionals are interested in the use of AI in radiology, particularly in early diagnosis leading to better patient outcomes. In this podcast we will explore how AI can aid in early detection, accurate interpretation of imaging scans and reduce diagnostic errors. This episode is joined by Associate Professor Michael Franco, a dual trained in medical oncology and palliative care and also the digital health director at Monash in Melbourne. He is featured with Professor Catherine Jones Cardiothoracic Radiologist I-Med Radiology and Clinical Director of Radiology at Redland Hospital, Brisbane and an expert on the Cancer Australia Expert Group for National Lung Cancer Screening Program. And accompanied by Dr Diane Pascoe a Consultant Radiologist and Deputy Director of Medical Imaging at Royal Melbourne Hospital.

In this TOGA Podcast the speakers discuss Antibody Drug Conjugates (ADCs) – An Emerging Treatment Platform in Lung Cancer. The discussion explores the different molecules and mechanisms of drugs currently available, trial results and the subsequent place of ADCs in the Lung Cancer. Furthermore, our guests expand upon the management of patients receiving these drugs. A/Prof Melissa Moore, Medical Oncologist at St Vincent’s Hospital Melbourne, is joined in this conversation by fellow medical oncologists A/Prof Tom John from Peter MacCallum Cancer Centre in Melbourne and A/Prof Adnan Nagrial from Westmead Hospital in Sydney.

This TOGA Podcast discusses Lung cancer Screening and Moving from Concept to Roll Out. The conversation explores the International Lung Cancer Screening Trial and overseas experience of recruitment, the challenges of reaching different population groups, some of whom stand to benefit most from the LCSP, and what it will mean for healthcare workload. The discussion explores the role of Federal and State jurisdictions in the management of the program. A/Prof Emily Stone, Head of Thoracic Medicine in the Dept of Thoracic Medicine and Lung Transplantation at St Vincent’s Hospital Sydney, is joined by A/Prof Gavin Wright Director of Surgical Oncology and a Thoracic Surgeon at St Vincent’s Hospital in Melbourne, A/Prof Nicole Rankin, an implementation scientist from The University of Melbourne with expertise in lung cancer and A/Prof Annette McWilliams who is a respiratory Physician at Fiona Stanley Hospital in Perth and clinical lead for the Thoracic Tumour Collaborative for Western Australia. This podcast is produced in support of lung cancer awareness month. Throughout the month of November please help spread awareness of lung cancer. If you want to find out more about lung cancer, get involved or donate towards lung cancer research- please go to TOGA's website at www.thoraciconcology.org.au For more information on the program https://thoraciconcology.org.au/lung-cancer-screening-program/

This TOGA Podcast discusses strategies for enhancing patients’ recovery from lung cancer resection in light of new and emerging data for new peri-operative therapies that improve survival. The conversation explores the guidelines available, the changing landscape for the patient with neoadjuvant and adjuvant management options, and the multidisciplinary considerations to optimise the care of patients. Dr Jazmin Eckhaus, a thoracic surgeon from The Austin, Melbourne, is joined by A/Prof Emily Stone, Head of Thoracic Medicine in the Dept of Thoracic Medicine and Lung Transplantation at St Vincent’s Hospital Sydney, A/Prof Melissa Moore, a medical oncologist from St Vincent’s in Melbourne and Chair of the TOGA Education Committee and Professor Catherine Granger, Head of Physiotherapy Research at The Royal Melbourne Hospital and an Associate Professor of Physiotherapy at The University of Melbourne in Australia. Professor Granger is a cardiorespiratory physiotherapist and clinician scientist with expertise in physical activity and exercise for cancer patients’ populations.

This TOGA Podcast discusses the data surrounding air pollution and lung cancer. The discussion delves into Nature and nurture and lung cancer risk and implications for future screening. Associate Professor Tom John, Medical Oncologist from Peter MacCallum Cancer Centre, is joined by Professor Charles Swanton, The Group Leader at the Cancer Therapeutics Laboratory at the London Research Institute and Medical Oncologist from University College in London, Associate Professor Venessa Chin, a Medical Oncologist from St Vincent’s Private Hospital, Kinghorn Cancer Centre and Garvan Institute and Dr Tracy Leong, Respiratory Physician from Austin Health, Melbourne and President of the Victorian Branch, and Director of Lung Cancer, for TSANZ.

In this TOGA Podcast, we discuss what defines operability in locally advanced stage III NSCLC. A/Professor Tim Clay, Medical Oncologist from St John of God Subiaco and Rockingham General is joined by Professor Lucy Morgan, Board Chair of the Lung Foundation of Australia and Respiratory Physician from Concord & Nepean Hospitals; A/Professor Phillip Antippa, Cardiothoracic surgeon and the Head of Thoracic Surgical Services at the Royal Melbourne Hospital and the VCCC and also Dr Qurrat van den Blink, Radiation Oncologist from GenesisCare based in Perth (Joondalup) and Albany.

In this TOGA Podcast, Australian medical oncologist, Associate Professor Chee Lee, St George Hospital, Kogarah, is joined by medical oncologist Dr Tristan Barnes, Royal North Shore Hospital, Sydney, and Dr Alex Davis, PhD candidate and medical oncologist at Chris O’Brien Lifehouse, Sydney. They discuss treatment of patients with non-small cell lung cancer with KRAS mutations, the role of co-mutations, and biomarkers that are negative predictors of response. Furthermore, the speakers give an update on current clinical research and approval status of KRAS inhibitors as well as the clinical need for the availability of KRAS inhibitors in Australia.

In this TOGA Podcast, Australian medical oncologist Dr Jenny Lee at Chris O’Brien Lifehouse, Sydney, is joined by medical oncologist Professor Nick Pavlakis, from Royal North Shore Hospital in Sydney and Lisa Briggs, Stage IV lung cancer survivor, Author, Osteopath and Exercise Physiologist who provides her own personal experience after being diagnosed with ALK+ non-small cell lung cancer in 2014. They discuss treatment of patients with non-small cell lung cancer with ALK mutations, the latest updates on ALK targeted therapies, the emergence of resistance, and how the choice of ALK inhibitor should be made between clinician and patient, taking into account potential side-effects, their management and the impact on the particular patient’s lifestyle.

In this TOGA Podcast, and on International Women’s Day 2023, we celebrate female leadership in medical research. We explore the challenges and success pathways across different career stages for women who work in medical oncology and clinical research. Associate Professor Prunella Blinman, head of the medical oncology department at Concord Hospital and past chair of the Medical Oncology Group of Australia, is joined by Assistant Professor Narjust Florez, Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at the Dana-Farber Brigham Cancer Center; Professor Lorraine Chantrill, medical oncologist and Head of Service for Medical Oncology across the Illawarra and Area Clinical Director of Clinical Trials; and Dr Rebecca Tay, medical oncologist at Royal Hobart Hospital and former clinical research fellow in lung cancer at The Christie NHS Foundation Trust in Manchester, United Kingdom. https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.10503

Recent studies in NSCLC patients with ALK or EGFR mutations and brain metastases, demonstrated greater benefit from the use of specific targeted therapies. In this Podcast, Associate Professor Paul Mitchell, Medical Oncologist from the Olivia Newton-John Cancer Centre, is joined by Dr Fiona Hegi-Johnson, Radiation Oncologist, Peter MacCallum Cancer Centre in Victoria, and Dr Dasantha Jayamanne, Radiation Oncologist, Genesis Care and Royal Northshore Hospital in NSW to discuss the management of brain metastases in NSCLC. They discuss the current data, the role of stereotactic radiation therapy (SRS, SABR, SBRT) and molecular drivers of ALK and EGFR in the management of these patients. Complex care is also discussed, as are intricacies and clinical considerations behind choosing and implementing care in NSCLC patients with brain metastases.